No abstract available.

The study was undertaken to detemine the effect of fractionated high-dose total lymphoid irradiation (TLI) onthe servival of skin allograft despite major histocompatibility difference. Total lymphoid irraditation is arelatively safe form of radiotherapy, has been used extensively to treat lymphoid malignancies in humans with fewside effects. A total of 90 rats, Sprague-Dawley rat as recipient and Wistar rat as donor, were used for theexperiment, of which 10 rats were used to determine mixed lymphocyte response (MLR) for antigenic difference andskin allografts was performed in 30 rats given total lymphoid irradiation to assess the immunosuppressive effectof total lymphoid irradiation despite major histocompatibility difference. In addition, the peripheral white bloodcell counts and the proportion of lymphocytes was studied in 10 rats given total lymphoid irradiation but no skingraft to determine the effects of bone marrow suppression. The results obtained are summerized as follows. 1. Theoptimum dose of total lymphoid irradiation was between 1800 rads to 2400 rads. 2. The survival of skin graft onrats given total lymphoid irradiation (23.2±6.0days) was prolonged about three folds as compared to unirradiated-control (8.7±1.3 days). 3. Total lymphoid irradiation resulted in a severe leukopneia with marked lymphopenia,but the count was normal by the end of 3rd week. 4. The study suggests that total lymphoid irradiation is anonlethal procedure that could be used successfully in animals to transplant allograft across major-histocompatibility barriers.
Allografts ; Animals ; Bone Marrow ; Histocompatibility ; Humans ; Lymphatic Irradiation ; Lymphocytes ; Radiotherapy ; Rats ; Rats, Sprague-Dawley ; Skin ; Tissue Donors ; Transplants

The effect of radiation on the liver should be of unusual interest in as much as there are two highly specialized kinds of epithelium besides an important endothelial system and vascular and fibrous elements tocompare, But there are several difficulites in the way of knowledge of the sensitivity and reaction of the liverto radiation. Perhaps the most important is the regenerative abillity of the liver cells. It has been assumed that the liver as an organ is relatively resistant to radiation injury. Yet there are reports of necrosis of the liverin man resulting from doses of radiation which have not caused a skin reaction or any demonstrable effect on the stomach. The author made an experiment to elucidate more clearly the changes in resum enezymes and histopathology of rat's liver following irradiation to the liver with a single dose of 2,000 rads. The resuls obtained are asfollows; 1. Serum SGOT activities were significatnly elevated, 1 and 2 weeks after irradiation, and normalized after 4 weeks. 2. Serum SGPT activities were significantly elevated 2 weeks after irradiation, and normalized after4 weeks. 3. Alakline phosphatase activity were significantly elevated 1, 2 and 4 weeks after irradiation, and normalized after 8 weeks. 4. Histopathologic changes were focal necrosis, inflammatory cell infiltration, loss of intra cytoplasmic glycogen particles, and vacuolar degenerations of hepatocytes. It appeared marked 2 weeks after irradiation, restored after 4 weeks, and normalized after 8 weeks.
Alanine Transaminase ; Aspartate Aminotransferases ; Cytoplasm ; Epithelium ; Glycogen ; Hepatitis ; Hepatocytes ; Liver ; Necrosis ; Radiation Injuries ; Skin ; Stomach

A study has been made on the skin response of mouse hind limb to radiation to evaluate the difference of skin response to superfractionation and conventional fractionation schedules, and to optimize the time interval betweenfractions and the dose per fraction in the superfractionated irradiation. 96 mouse hind limbs were dvided into 12groups and were irradiated with 10 consecutive fractions by intervals of 6, 12 or 24 hours and dose per fractionsof 400, 500, 600 or 700 rads. The skin changes of the irradiated hind limb were observed for 30 days and the skin response were analyzed. The results are as follows; 1. There was no significant difference of early skin response along the time interval, from 6 to 24 hours, up to 600 rads per fraction. 2. Mean duration to maximum skin reaction in superfractionation (15.48±2.80 days) is shorter than in conventional fractionation (18.05±3.20 days)by 2.57 days. (p<0.05). 3. Optimum time interval betwen fractions in superfractionation may be 6 hours or less. 4. Optimum dose per fraction in superfractionation may be 500 rads or less.
Animals ; Appointments and Schedules ; Extremities ; Mice ; Skin

NO abstract available.
Brain* ; Neoplasm Metastasis*

Radiologic findings of the 29 cases of radiation pneumonitis and fibrosis diagnosed by chest radiography atSeoul National University Hospital were evaluated and compared with clinical symptoms according to the passage oftime after radiation therapy. The resuls were as follows; 1. The first radiographic signs of radiation pneumonitisand fibrosis were observed 7.6 weeks and 19.3 weeks after radiation therapy respectively. Especially in 8 cases ofsmall cell ca., they were found 5.6 weeks and 10.4 weeks, appearing slinghtly earlier than those of 12 cases ofsquamous cell ca. of lung. 2. The appearing time and severity of the radiographic changes of radiation pneumonitisand fibrosis had no specific relationship with field size, tumor dose or time-dose-fractionation factors of thetreatment. 3. The most constant and characteristic radiological finding of radiation pneumonitis was the sharp andstraight margin of the lesion, which was not that of normal anatomical structures of the lung. Other findings werediffuse haziness, indistinct normal pulmonary markings, alveolar and nodular densities, air-bronchograms andindistinctness of heart border. In radiation fibrosis stage, the lesion characteristic and constant finding. Otherfindings were indistinctness of heart border, diaphragmatic tenting and compensatory emphysema.
Emphysema ; Fibrosis ; Heart ; Lung ; Radiation Pneumonitis ; Radiography ; Thorax

No abstract available.
Cyclophosphamide*

From 1980 to 1986, 26 patients with metastatic carcinoma of the neck node from an unknown primary site were seen in the Department of Therapeutic Radiology of Seoul National University Hospital. Among these, three patients were excluded from further analysis due to incomplete treatment. So a retrospective analysis was undertaken on 23 patients who had complete treatment with radiation therapy alone or in combination with surgical treatment and chemotherapy. The overall three year actuarial survival rate was 32%. According to the staging system of the American Joint Committee on Cancer, the three year survival rates with N2 and N3 patients were 43% and 13%, respectively. In 16 patients with squamous cell carcinoma and seven with non-squamous cell carcinoma, the three year survival rates were 34% and 29%, respectively. Analysis according to site of nodal involvement was also done. Patients with cervical node and supraclavicular node involvement recorded 44% and 17% of three year survival rate, respectively. In the study, six patients eventually manifested the primary sites (three in the lung, one in the esophagus, one in the stomach, one in the nasopharynx). Presence of the primary site seemed to influence the prognosis (17% vs 38%). In analyzing the prognostic factors, the nodal stage and site of nodal involvement were important prognostic factors, and the presence of a primary site seemed to influence the patients' survival, but histology did not.
Carcinoma, Squamous Cell ; Drug Therapy ; Esophagus ; Humans ; Joints ; Lung ; Neck* ; Prognosis ; Radiation Oncology ; Retrospective Studies ; Seoul ; Stomach ; Survival Rate

PURPOSE: This study was undertaken to evaluate the treatment outcome and side effects of accelerated radiotherapy (RT) using concomitant boost for stage III non-small cell lung cancer (NSCLC). METHODS: Between April 1991 and December 1994, 102 patients with stage III NSCLC who had the favorable prognostic factors by CALGB criteria, were treated with concomitant boost radiotherapy. Patients were treated with standard large fields to 54 Gy in 6 weeks. The boost treatment was administered concomitantly during the last 2 weeks with a dose of 13 Gy in 10 fractions. The interfraction interval was at least 6 hours. The total tumor dose was 66-70 Gy, given over 6 weeks. RESULTS: With 30 months median follow-up period for survivors, median survival was 15 months with 2 and 3-year overall survival rates of 34% and 19%, respectively. Thirty patients (29%) who had achieved complete remission after RT showed significantly better 2-year survival rates than those without complete remission (58% vs 22%, p 0.001). Local failure and distant metastases as the first or only failure occurred in 40 (44%) and 13 (14%), respectively, and ultimate local and distant failure rates were 45% and 29%, respectively. Although Grade IV esophageal complication of T-E fistula was observed in one patient, most patients with pulmonary complication showed mild, transient radiation pneumonitis. CONCLUSION: This result suggests that the treatrnent of stage III NSCLC with concomitant boost RT may improve survival rates without enhanced radiation induced toxicity compared with conventional RT. Further investigation of dose escalation by conformal radiotherapy of combining chemotherapy and accelerated RT is warranted.
Carcinoma, Non-Small-Cell Lung ; Drug Therapy ; Fistula ; Follow-Up Studies ; Humans ; Neoplasm Metastasis ; Radiation Pneumonitis ; Radiotherapy* ; Radiotherapy, Conformal ; Small Cell Lung Carcinoma* ; Survival Rate ; Survivors ; Treatment Outcome

Whole brain irradiation is one mode in the treatment of brain cancer and brain metastasis, but it might cause brain injury such as brain necrosis. It has been studied whether the dose distribution could be a cause of brain injury. The dose distribution in whole brain irradiated by Co-0 beam has been measured by means of calibrated TLD chips inserted in the brain of Humanoid phantom. The following results were obtained. 1. Dose distribution on each transverse section of the brain was uniform. 2. On the midsagital plane of the brain, the dose was highest in upper portion and lowest in lower portion, varying 8 from 104% to 90%. 3. When the radiation field includes free space of 2cm or more width out of the head, the dose distribution in the whole brain is almost independent of the field width. 4. It is important to determine adequate shielding area and to set shielding block exactly in repetition of treatment.
Brain Injuries ; Brain Neoplasms ; Brain* ; Head ; Necrosis ; Neoplasm Metastasis ; Radiotherapy*